Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield

NCT ID: NCT05140057

Last Updated: 2021-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Small bowel capsule endoscopy (SBCE) has become an important tool in clinical practice since its introduction in 2000. This non-invasive method allows the visualization of small bowel mucosa, being essential in the management of many conditions, such as suspected small bowel bleeding, inflammatory bowel diseases and intestinal polyposis syndromes. Despite recommendations concerning SBCE in different pathologies, there are still some technical concerns to be addressed. The optimal preparation for SBCE has been one of these controversial issues.

Currently, the European Society of Gastrointestinal Endoscopy (ESGE) recommends that patients ingest a purgative agent (2L of polyethylene glycol, PEG) and antifoaming agents for SBCE, because it was associated with a better visualization. However, it remains unclear which is the optimal timing for purgative use. Furthermore, the use of a booster agent after capsule ingestion is already performed in colon capsule endoscopy, but less is known about its application in SBCE. Also, it remains to be clarified whether a better visualization results in higher diagnostic yield and impacts patients' outcomes.

Therefore, the global aim of this prospective, randomized, multi-centric study is to determine the optimal timing and preparation for small-bowel capsule endoscopy (regardless of the equipment used), comparing four groups of different preparation protocols:

* Protocol 1) 1L of Moviprep® solution the night before the procedure
* Protocol 2) 1L of Moviprep® solution up to 2h before the procedure
* Protocol 3) 0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum (assessed with real-time viewer)
* Protocol 4) 1L of Moviprep® solution after the capsule had reached the duodenum (assessed using real-time viewer)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obscure Gastrointestinal Bleeding

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Small bowel capsule endoscopy Obscure gastrointestinal bleeding Bowel preparation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protocol 1

1L of Moviprep® solution the night before the procedure

Group Type EXPERIMENTAL

Moviprep

Intervention Type COMBINATION_PRODUCT

Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Protocol 2

1L of Moviprep® solution up to 2h before the procedure

Group Type EXPERIMENTAL

Moviprep

Intervention Type COMBINATION_PRODUCT

Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Protocol 3

0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum

Group Type EXPERIMENTAL

Moviprep

Intervention Type COMBINATION_PRODUCT

Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Protocol 4

1L of Moviprep® solution after the capsule had reached the duodenum

Group Type EXPERIMENTAL

Moviprep

Intervention Type COMBINATION_PRODUCT

Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moviprep

Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be 18 years old or older
* Present OGIB (either occult or overt)
* Agree with study's procedures and have signed the informed consent for the study and SBCE, prior to SBCE procedure

Exclusion Criteria

* Patients performing capsule endoscopy in urgent setting for overt obscure GI bleeding
* Inpatients or bedridden
* History of surgery of the esophagus, stomach, small bowel, or colon
* History of abdominal or pelvic radiation therapy
* Suspected or confirmed stenosis or occlusion
* Suspected or confirmed bowel perforation
* Severe comorbidities, as defined by grade 3 "severe decompensation" in the Adult Comorbidity Evaluation-27 index (ACE-27)
* Pregnant women
* Patients using narcotics or prokinetics in the week before the SBCE
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria Manuela Estevinho

Medical Doctor, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia/Espinho

Vila Nova de Gaia, , Portugal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Portugal

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Manuela Estevinho

Role: primary

Rolando Pinho

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0001

Identifier Type: -

Identifier Source: org_study_id